|

Lunsekimig Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since June 2026

Also known as: SAR443765

Pipeline

Phase 3: 2

Top Sponsors

  • Sanofi2

Indications

  • Chronic Obstructive Pulmonary Disease2
  • COPD2

Birmingham, Alabama1 trial

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

University of Alabama at Birmingham- Site Number : 8400003

Phase 3

Chandler, Arizona1 trial

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Chandler Clinical Research Trials- Site Number : 8400025

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.